Erythroid maturation agent

This page covers all Erythroid maturation agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Activin A; TGF-β superfamily ligands, TGF-β superfamily ligands (GDF11, activin A).

Targets

Activin A; TGF-β superfamily ligands · TGF-β superfamily ligands (GDF11, activin A)

Marketed (1)

• Luspatercept Injectable Product · Sun Yat-sen University · Hematology
  Luspatercept is an erythroid maturation agent that binds to and inhibits activin A and related proteins, promoting late-stage erythroid differentiation and hemoglobin production.

Phase 2 pipeline (1)

• Luspatercept Injection [Reblozyl] · Groupe Francophone des Myelodysplasies · Oncology
  Luspatercept is a recombinant fusion protein that acts as a ligand trap for members of the TGF-β superfamily, modulating Smad2/3 signaling to enhance erythroid maturation.